Reminder: Corporate Access: *This Week* SAN, BAYN, ARGX and REC: Barclays Conversations with the C-Suite in European Healthcare 2026

Research evidence excerpt

Reminder: Corporate Access: *This Week* SAN, BAYN, ARGX and REC: Barclays Conversations with the C-Suite in European Healthcare 2026

Meet the Analysts

James Gordon is a Director and Head of the European

Pharma & Biotech Equity Research team at Barclays.

James joined Barclays in November 2025, having spent

c.20 years covering European Pharma & Biotech at J.P.

Morgan, where he was part of a team consistently top

ranked in the Institutional Investor / Extel survey. Prior to

Healthcare Equity Research James worked in Strategy

Consulting, focusing on Pharmaceuticals. James holds a

1st-class BSc in Genetics from University College London,

with a focus on Population Genetics and Statistics.

View Analyst Page

Charles Pitman-King joined Barclays in 2022 as a VP in the

European pharmaceutical team to cover a selection of

mid-cap companies. His previous experience includes

covering both mid-cap European and large-cap US

pharmaceutical companies since 2018, as well as broad

sector themes, such as the rapidly evolving COVID-19

pandemic and sector ESG themes. Prior to this, he has also

had experience covering the Aerospace and Defence

sector, and working in financial modelling. He holds a first

class Masters in Mathematics from Durham University and

has been a CFA charterholder since 2019.

Hassan Al-Wakeel, CFA, is a Managing Director and Head of

European Medical Technology & Services Equity Research

at Barclays. He ranked #1 in his sector in the 2025 and

2024 Institutional Investor / Extel survey. Hassan joined

Barclays in 2017; he has over a decade of experience in

equity research, previously working as a Global MedTech

analyst at GLG Partners and starting his career at Deutsche

Bank. He is a CFA Charterholder and graduated with a First